Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling?

Journal of the National Cancer Institute

Volumn 105, Issue 11, 2013, Pages 762-765

  Duda, Dan G ^a   Munn, Lance L ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; AXITINIB; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CABOZANTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; PAZOPANIB; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE MARROW CELL; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; METASTATIC COLORECTAL CANCER; MONOTHERAPY; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; STOMACH CANCER; TARGET CELL; THYROID MEDULLARY CARCINOMA; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; COMPUTER SIMULATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878878984     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt114     Document Type: Editorial

References (24)

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
2. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368-4380. (Pubitemid 35266299)
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676. (Pubitemid 36749215)
4. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. doi:10.1200/JCO.2012.46.3653.
5. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6): 327-338.
6. Lambrechts D, Lenz HJ, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31(9):1219-1230.
7. Finley SD, Popel AS. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst. 2013;105(11):802-811.
8. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239-3247.
9. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27(18):3027-3035.
10. Dowlati A, Gray R, Johnson DH, et al. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2006;24S:7027.
11. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24(2):217-227. (Pubitemid 46622051)
12. Hegde PS, Jubb AM, Chen D, et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res. 2013;19(4):929-937.
13. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119-2127.
14. Jayson GC, de Haas S, Delmar P, et al. Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab. Eur J Cancer. 2011;47:S96.
15. Xu L, Duda DG, di Tomaso E, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009;69(20):7905-7910.
16. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94(6):715-725. (Pubitemid 28436004)
17. Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008;456(7223):814-818.
18. Duda DG, Willett CG, Ancukiewicz M, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15(6):577-583.
19. Meyerhardt JA, Ancukiewicz M, Abrams TA, et al. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012;7(6): e38231.
20. Raut CP, Boucher Y, Duda DG, et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012;7(2):e26331.
21. Tolaney SM, Duda DG, Boucher Y, et al. A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). J Clin Oncol. 2012;30:(suppl; abstr 1026).
22. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27(18):3020-3026.
23. Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013;19:1157-1166.
24. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012;13:724-733.